University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Andrew Leavitt, M.D.

Blood disorder specialist

Dr. Andrew Leavitt is director of the UCSF Non-malignant Hematology Program and co-director of UCSF Comprehensive Hemophilia Treatment Center. He is a hematologist who treats patients with non-malignant blood diseases, including bleeding disorders such as hemophilia and von Willebrand disease, platelet function disorders, thrombocytopenia, including ITP, venous thromboembolic disorders, neutropenia and anemia. He also is the medical director of the Adult Blood and Marrow Transplant Laboratory and is internationally known for his studies of megakaryocyte development. His research also focuses on improving the treatment and outcome of patients with venous thromboembolic diseases.

Leavitt obtained a medical degree at Harvard Medical School. He completed an internal medicine residency and was chief medical resident at the University of Michigan, Ann Arbor, and completed a hematology and oncology fellowship and a transfusion medicine fellowship at UCSF. He joined the UCSF faculty in 1992 and is a professor-in-residence in the departments of Medicine and Laboratory Medicine. Leavitt has served on the editorial boards of the journal BLOOD and the Journal of Clinical Investigation. He currently serves on the editorial board of the Journal of Clinical and Translational Science.


Hematology and Blood and Marrow Transplant
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Hemophilia Treatment Center
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Phone: (415) 353-2421
Fax: (415) 353-2467

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Andrew Leavitt


Harvard School of Medicine 1984


University of Michigan Hospital, Internal Medicine 1988


UCSF Medical Center, Hematology/Oncology 1991
UCSF Medical Center, Transfusion Medicine 1992

Selected Research and Publications

  1. Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD. Hematopoietic Expression of Oncogenic BRAF Promotes Aberrant Growth of Monocyte-Lineage Cells Resistant to PLX4720. Mol Cancer Res. 2013 Dec; 11(12):1530-41.
  2. Jacquot C, Moayeri M, Kim B, Shugarts S, Lynch KL, Leavitt AD. Prolonged ceftriaxone-induced immune thrombocytopenia due to impaired drug clearance: a case report. Transfusion. 2013 Nov; 53(11):2715-21.
  3. Choi YS, Patena W, Leavitt AD, McManus MT. Widespread RNA 3'-end oligouridylation in mammals. RNA. 2012 Mar; 18(3):394-401.
  4. Leavitt AD, Hamlett I. Homologous recombination in human embryonic stem cells: a tool for advancing cell therapy and understanding and treating human disease. Clin Transl Sci. 2011 Aug; 4(4):298-305.
  5. Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck SG, Roop DR, Leavitt AD, Li Y. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.
  6. Leavitt AD. A vote for scientists as politicians. Science. 2011 Feb 25; 331(6020):1010.
  7. Leavitt AD. Are there more tricks in the bag for treating thrombocytopenia? J Clin Invest. 2010 Nov; 120(11):3807-10.
  8. King FW, Ritner C, Liszewski W, Kwan HC, Pedersen A, Leavitt AD, Bernstein HS. Subpopulations of human embryonic stem cells with distinct tissue-specific fates can be selected from pluripotent cultures. Stem Cells Dev. 2009 Dec; 18(10):1441-50.
  9. Alian A, Griner SL, Chiang V, Tsiang M, Jones G, Birkus G, Geleziunas R, Leavitt AD, Stroud RM. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci U S A. 2009 May 19; 106(20):8192-7.
  10. Nicholas CR, Gaur M, Wang S, Pera RA, Leavitt AD. A method for single-cell sorting and expansion of genetically modified human embryonic stem cells. Stem Cells Dev. 2007 Feb; 16(1):109-17.
  11. Gaur M, Kamata T, Wang S, Moran B, Shattil SJ, Leavitt AD. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost. 2006 Feb; 4(2):436-42.
  12. Watson SP, Bahou WF, Fitzgerald D, Ouwehand W, Rao AK, Leavitt AD. Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. J Thromb Haemost. 2005 Sep; 3(9):2098-101.
  13. Kamata T, Kang J, Lee TH, Wojnowski L, Pritchard CA, Leavitt AD. A critical function for B-Raf at multiple stages of myelopoiesis. Blood. 2005 Aug 1; 106(3):833-40.
  14. Kerrigan SW, Gaur M, Murphy RP, Shattil SJ, Leavitt AD. Caspase-12: a developmental link between G-protein-coupled receptors and integrin alphaIIbbeta3 activation. Blood. 2004 Sep 1; 104(5):1327-34.
  15. Gaur M, Murphy GJ, Frampton J, Leavitt AD. Using retroviruses to express genes in primary megakaryocyte lineage cells. Methods Mol Biol. 2004; 273:381-96.
  16. Kamata T, Pritchard CA, Leavitt AD. Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation. Blood. 2004 Apr 1; 103(7):2568-70.
  17. Murphy GJ, Göttgens B, Vegiopoulos A, Sanchez MJ, Leavitt AD, Watson SP, Green AR, Frampton J. Manipulation of mouse hematopoietic progenitors by specific retroviral infection. J Biol Chem. 2003 Oct 31; 278(44):43556-63.
  18. Eto K, Murphy R, Kerrigan SW, Bertoni A, Stuhlmann H, Nakano T, Leavitt AD, Shattil SJ. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12819-24.
  19. Shattil SJ, Leavitt AD. All in the family: primary megakaryocytes for studies of platelet alphaIIbbeta3 signaling. Thromb Haemost. 2001 Jul; 86(1):259-65.
  20. Gaur M, Murphy GJ, deSauvage FJ, Leavitt AD. Characterization of Mpl mutants using primary megakaryocyte-lineage cells from mpl(-/-) mice: a new system for Mpl structure-function studies. Blood. 2001 Mar 15; 97(6):1653-61.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.